{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T05:35:21Z","timestamp":1766208921671,"version":"3.48.0"},"reference-count":41,"publisher":"Japanese Society of Internal Medicine","issue":"24","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2025,12,15]]},"DOI":"10.2169\/internalmedicine.5467-25","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T18:07:42Z","timestamp":1749060462000},"page":"3531-3536","source":"Crossref","is-referenced-by-count":0,"title":["Primary Hyperparathyroidism with Severe Vitamin D Deficiency in Chronic Kidney Disease"],"prefix":"10.2169","volume":"64","author":[{"given":"Tsuyoshi","family":"Oshiro","sequence":"first","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Showa Medical University Fujigaoka Hospital, Japan"},{"name":"Department of Medical Education, Showa Medical University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Nishiwaki","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Showa Medical University Fujigaoka Hospital, Japan"},{"name":"Institute of Clinical Epidemiology (iCE), Showa Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reiji","family":"Takami","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Showa Medical University Fujigaoka Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Omiya","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Showa Medical University Fujigaoka Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"Barroga","sequence":"additional","affiliation":[{"name":"Medical English Education Center, Showa Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumihiko","family":"Koiwa","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Showa Medical University Fujigaoka Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. Press DM, Siperstein AE, Berber E, et al. The prevalence of undiagnosed and unrecognized primary hyperparathyroidism: a population-based analysis from the electronic medical record. Surgery 154: 1232-1238, 2013.","DOI":"10.1016\/j.surg.2013.06.051"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Sociedade Brasileira de Endocrinologia e Metabologia; Bandeira F, Griz L, Chaves N, et al.; Sociedade Brasileira de Endocrinologia e Metabologia. Diagnosis and management of primary hyperparathyroidism - a scientific statement from the Department of Bone Metabolism, the Brazilian Society for Endocrinology and Metabolism. Arq Bras Endocrinol Metabol 57: 406-424, 2013.","DOI":"10.1590\/S0004-27302013000600002"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Yeh MW, Ituarte PH, Zhou HC, et al. Incidence and prevalence of primary hyperparathyroidism in a racially mixed population. J Clin Endocrinol Metab 98: 1122-1129, 2013.","DOI":"10.1210\/jc.2012-4022"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Meng L, Su C, Shapses SA, Wang X. Total and free vitamin D metabolites in patients with primary hyperparathyroidism. J Endocrinol Invest 45: 301-307, 2022.","DOI":"10.1007\/s40618-021-01633-1"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Moosgaard B, Vestergaard P, Heickendorff L, Melsen F, Christiansen P, Mosekilde L. Vitamin D status, seasonal variations, parathyroid adenoma weight and bone mineral density in primary hyperparathyroidism. Clin Endocrinol (Oxf) 63: 506-513, 2005.","DOI":"10.1111\/j.1365-2265.2005.02371.x"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Vaidya A, Curhan G, Paik JM, Wang M, Taylor EN. Physical activity and the risk of primary hyperparathyroidism. J Clin Endocrinol Metab 101: 1590-1597, 2016.","DOI":"10.1210\/jc.2015-3836"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Vaidya A, Curhan G, Paik JM, Wang M, Taylor EN. Body size and the risk of primary hyperparathyroidism in women: a cohort study. J Bone Miner Res 32: 1900-1906, 2017.","DOI":"10.1002\/jbmr.3168"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Vaidya A, Curhan GC, Paik JM, Kronenberg H, Taylor EN. Hypertension, antihypertensive medications, and risk of incident primary hyperparathyroidism. J Clin Endocrinol Metab 100: 2396-2404, 2015.","DOI":"10.1210\/jc.2015-1619"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Boehm BO, Rosinger S, Belyi D, Dietrich JW. The parathyroid as a target for radiation damage. N Engl J Med 365: 676-678, 2011.","DOI":"10.1056\/NEJMc1104982"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Griebeler ML, Kearns AE, Ryu E, et al. Thiazide-associated hypercalcemia: incidence and association with primary hyperparathyroidism over two decades. J Clin Endocrinol Metab 101: 1166-1173, 2016.","DOI":"10.1210\/jc.2015-3964"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Holick MF. Vitamin D deficiency. N Engl J Med 357: 266-281, 2007.","DOI":"10.1056\/NEJMra070553"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Schini M, Jacques RM, Oakes E, Peel NFA, Walsh JS, Eastell R. Normocalcemic hyperparathyroidism: study of its prevalence and natural history. J Clin Endocrinol Metab 105: e1171-e1186, 2020.","DOI":"10.1210\/clinem\/dgaa084"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Tuna MM, \u00c7al\u0131\u015fkan M, \u00dcnal M, et al. Normocalcemic hyperparathyroidism is associated with complications similar to those of hypercalcemic hyperparathyroidism. J Bone Miner Metab 34: 331-335, 2016.","DOI":"10.1007\/s00774-015-0673-3"},{"key":"14","unstructured":"14. Leslie SW, Levine SN. Normocalcemic Hyperparathyroidism. StatPearls, Treasure Island, 2024."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Ramasamy I. Vitamin D metabolism and guidelines for Vitamin D supplementation. Clin Biochem Rev 41: 103-126, 2020.","DOI":"10.33176\/AACB-20-00006"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Yadav SK, Mishra SK, Mishra A, et al. Changing profile of primary hyperparathyroidism over two and half decades: a study in tertiary referral center of North India. World J Surg 42: 2732-2737, 2018.","DOI":"10.1007\/s00268-018-4575-0"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Walker MD, Cong E, Lee JA, et al. Vitamin D in Primary hyperparathyroidism: effects on clinical, biochemical, and densitometric presentation. J Clin Endocrinol Metab 100: 3443-3451, 2015.","DOI":"10.1210\/jc.2015-2022"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Rolighed L, Rejnmark L, Sikjaer T, et al. Vitamin D treatment in primary hyperparathyroidism: a randomized placebo controlled trial. J Clin Endocrinol Metab 99: 1072-1080, 2014.","DOI":"10.1210\/jc.2013-3978"},{"key":"19","doi-asserted-by":"crossref","first-page":"e10415","DOI":"10.1002\/jbm4.10415","volume":"4","author":"UM Kabadi","year":"2020","unstructured":"19. Kabadi UM. Low 25-hydroxyvitamin D in primary hyperparathyroidism: enhanced conversion into 1,25-hydroxyvitamin D may not be "true" deficiency. JBMR Plus 4: e10415, 2020.","journal-title":"JBMR Plus","ISSN":"https:\/\/id.crossref.org\/issn\/2473-4039","issn-type":"print"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Walker MD, Cong E, Lee JA, et al. Low vitamin D levels have become less common in primary hyperparathyroidism. Osteoporos Int 26: 2837-2843, 2015.","DOI":"10.1007\/s00198-015-3199-6"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Holick MF. High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc 81: 353-373, 2006.","DOI":"10.4065\/81.3.353"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol 289: F8-F28, 2005.","DOI":"10.1152\/ajprenal.00336.2004"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Lo CW, Paris PW, Clemens TL, Nolan J, Holick MF. Vitamin D absorption in healthy subjects and in patients with intestinal malabsorption syndromes. Am J Clin Nutr 42: 644-649, 1985.","DOI":"10.1093\/ajcn\/42.4.644"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Bilezikian JP. Primary hyperparathyroidism. J Clin Endocrinol Metab 103: 3993-4004, 2018.","DOI":"10.1210\/jc.2018-01225"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Stein EM, Dempster DW, Udesky J, et al. Vitamin D deficiency influences histomorphometric features of bone in primary hyperparathyroidism. Bone 48: 557-561, 2011.","DOI":"10.1016\/j.bone.2010.10.004"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Moosgaard B, Vestergaard P, Heickendorff L, Melsen F, Christiansen P, Mosekilde L. Plasma 25-hydroxyvitamin D and not 1,25-dihydroxyvitamin D is associated with parathyroid adenoma secretion in primary hyperparathyroidism: a cross-sectional study. Eur J Endocrinol 155: 237-244, 2006.","DOI":"10.1530\/eje.1.02197"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Moosgaard B, Vestergaard P, Heickendorff L, Mosekilde L. Plasma 1,25-dihydroxyvitamin D levels in primary hyperparathyroidism depend on sex, body mass index, plasma phosphate and renal function. Clin Endocrinol (Oxf) 66: 35-42, 2007.","DOI":"10.1111\/j.1365-2265.2006.02680.x"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Armbrecht HJ, Boltz MA, Ritter CS, Brown AJ. Parathyroid hormone stimulation of the renal 25-hydroxyvitamin D-1\u03b1-hydroxylase - effect of age and free radicals. J Steroid Biochem Mol Biol 103: 330-333, 2007.","DOI":"10.1016\/j.jsbmb.2006.12.035"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Razzaque MS. Interactions between FGF23 and vitamin D. Endocr Connect 11: e220239, 2022.","DOI":"10.1530\/EC-22-0239"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Wortsman J, Haddad JG, Posillico JT, Brown EM. Primary hyperparathyroidism with low serum 1,25-dihydroxyvitamin D levels. J Clin Endocrinol Metab 62: 1305-1308, 1986.","DOI":"10.1210\/jcem-62-6-1305"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Brown EM, Vickery AL. Case 32-1996 - a 44-year-old woman with a long history of intermittent hypercalcemia, a new neck mass, and hypercalcemic crisis. N Engl J Med 335: 1213-1220, 1996.","DOI":"10.1056\/NEJM199610173351608"},{"key":"32","unstructured":"32. Coen G, Bondatti F, de Matteis A, et al. Severe vitamin D deficiency in a case of primary hyperparathyroidism caused by parathyroid lipoadenoma, effect of 25OHD3 treatment. Miner Electrolyte Metab 15: 332-337, 1989."},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Ng CH, Chin YH, Tan MHQ, et al. Cinacalcet and primary hyperparathyroidism: systematic review and meta regression. Endocr Connect 9: 724-735, 2020.","DOI":"10.1530\/EC-20-0221"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Takeuchi Y, Nishida Y, Kondo Y, Imanishi Y, Fukumoto S. Evocalcet in patients with primary hyperparathyroidism: an open-label, single-arm, multicenter, 52-week, dose-titration phase III study. J Bone Miner Metab 38: 687-694, 2020.","DOI":"10.1007\/s00774-020-01097-y"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Schieferdecker A, Voigt M, Riecken K, et al. Denosumab mimics the natural decoy receptor osteoprotegerin by interacting with its major binding site on RANKL. Oncotarget 5: 6647-6653, 2014.","DOI":"10.18632\/oncotarget.2160"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Shalaby T, Anandappa S, Sivappriyan S, Kumar J. The use of denosumab in a nonagenarian with primary hyperparathyroidism. Eur Endocrinol 10: 151-152, 2014.","DOI":"10.17925\/EE.2014.10.02.151"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Nadarasa K, Theodoraki A, Kurzawinski TR, et al. Denosumab for management of refractory hypercalcaemia in recurrent parathyroid carcinoma. Eur J Endocrinol 171: L7-L8, 2014.","DOI":"10.1530\/EJE-14-0482"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Hu MI, Glezerman IG, Leboulleux S, et al. Denosumab for treatment of hypercalcemia of malignancy. J Clin Endocrinol Metab 99: 3144-3152, 2014.","DOI":"10.1210\/jc.2014-1001"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Leere JS, Karmisholt J, Robaczyk M, et al. Denosumab and cinacalcet for primary hyperparathyroidism (DENOCINA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol 8: 407-417, 2020.","DOI":"10.1016\/S2213-8587(20)30063-2"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Eremkina A, Krupinova J, Dobreva E, et al. Denosumab for management of severe hypercalcemia in primary hyperparathyroidism. Endocr Connect 9: 1019-1027, 2020.","DOI":"10.1530\/EC-20-0380"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Jumpertz von Schwartzenberg R, Elbelt U, Ventz M, et al. Palliative treatment of uncontrollable hypercalcemia due to parathyrotoxicosis: denosumab as rescue therapy. Endocrinol Diabetes Metab Case Rep 2015: 150082, 2015.","DOI":"10.1530\/EDM-15-0082"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/24\/64_5467-25\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T03:39:50Z","timestamp":1766201990000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/24\/64_5467-25\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":41,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.5467-25","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"type":"print","value":"0918-2918"},{"type":"electronic","value":"1349-7235"}],"subject":[],"published":{"date-parts":[[2025,12,15]]},"article-number":"5467-25"}}